monoclonal

Infliximab is a monoclonal antibody, a human-mouse chimeric monoclonal antibody that inhibits TNF-α and prevents TNF-α from interacting with TNFR1 and TNFR2. Infliximab can be used to treat Crohn's disease and rheumatoid arthritis.

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Carlumab is a high-affinity human monoclonal antibody that targets CCL2, blocking its interaction with the CCR2 receptor, thereby inhibiting CCL2-mediated tumour growth and suppressing the recruitment of monocytes/macrophages in the tumour microenvironment. It can be used for prostate and breast cancer research.

GSK3050002 (E-6071) is a humanized antibody targeting CCL20, which can be used to study immune system diseases and digestive system diseases.

Pritumumab (ACA 11) is a natural human IgG1 κ antibody that can be used to study glioblastoma and brain tumors.

Oregovomab (Alt-2 monoclonal antibody), a murine mAb, specifically targets CA125, inducing a cytotoxic immune response against tumor cells that express CA125 [1] [2].

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.

Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Ofatumumab is a humanized monoclonal antibody targeting CD20. Ofatumumab acts on CD20-expressing B lymphocytes, inducing antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC).

Bimagrumab (BYM338) is a human monoclonal antibody that binds to the activin type II receptor. Bimagrumab can be used to study diabetes and obesity.

Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases.

Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brain permeability and may be used to treat Alzheimer's disease (AD).

Tezepelumab (AMG 157) is a humanized monoclonal antibody (IgG2λ) targeting TSLP that prevents TSLP from interacting with its heterodimer receptor. Tezepelumab can be used to study advanced asthma disease.

Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.

Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.

Human IgG1 kappa, Isotype Control is a humanized IgG-like monoclonal antibody and an isotype control antibody for human IgG1κ.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.